Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Mol Neurobiol ; 57(9): 3860-3874, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32613466

RESUMEN

Early life and adulthood stress increase vulnerability for mental illness, and eventually trigger depression. N-3 polyunsaturated fatty acids (PUFA) have antidepressant effects, but their effect on rats exposed to combined stress has been not investigated. This study aimed to investigate whether n-3 PUFA supplementation had antidepressant-like effects in rat models of depression induced by a combination of chronic mild stress (CMS) and maternal separation (MS) through the modulation of the hypothalamic-pituitary-adrenal (HPA) axis and neurotransmission. Rats were fed the n-3 PUFA diet during the pre-weaning or post-weaning period or for lifetime, and allocated to different groups based on the type of induced stress: non-stress (NS), CMS + MS, or CMS alone. N-3 PUFA improved the depressive behaviors of the CMS alone and CMS + MS groups and modulated the HPA-axis by reducing the circulating adrenocorticotropic hormone, corticosterone, and corticotropin-releasing factor expression, and increasing glucocorticoid receptor expression. N-3 PUFA also modulated brain phospholipid fatty acid concentration, thus reducing inflammatory cytokines; improved the serotonergic pathway, thus increasing the expression of the brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), serotonin-1A receptor, and serum levels of serotonin; but did not affect glutamatergic neurotransmission. Furthermore, n-3 PUFA decreased the hippocampal expression of microRNA-218 and -132, increased that of microRNA-155, and its lifetime supplementation was more beneficial than pre- or post-weaning supplementation. This study suggests that n-3 PUFA has an antidepressant effect in rats exposed to combined stress, through the improvement of the HPA-axis abnormalities, the BDNF-serotonergic pathway, and the modulation of microRNAs.


Asunto(s)
Antidepresivos/farmacología , Ácidos Grasos Omega-3/farmacología , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Estrés Psicológico/complicaciones , Transmisión Sináptica/efectos de los fármacos , Hormona Adrenocorticotrópica/sangre , Animales , Antidepresivos/uso terapéutico , Conducta Animal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Encéfalo/metabolismo , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Hormona Liberadora de Corticotropina/sangre , Citocinas/metabolismo , Depresión/sangre , Depresión/tratamiento farmacológico , Dinoprostona/sangre , Ácidos Grasos/análisis , Ácidos Grasos Omega-3/uso terapéutico , Femenino , Hipocampo/metabolismo , Masculino , MicroARNs/genética , MicroARNs/metabolismo , Neurotransmisores/metabolismo , Fosfolípidos/metabolismo , Subunidades de Proteína/metabolismo , Ratas Wistar , Receptores de Glutamato/metabolismo , Serotonina/sangre , Estrés Psicológico/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA